Testing SW-682 in Advanced Solid Tumors
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug (SW-682) for people with advanced solid tumors that have stopped responding to standard treatments. It focuses on cancers with specific gene changes (NF2 or Hippo pathway) and aims to see if the drug can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a solid cancer that has spread to other parts of the body or cannot be removed by surgery, and it has not responded to or stopped working after previous treatments.
- Your cancer must be one of these types: mesothelioma, or a solid tumor with an NF2 mutation, or another change in the Hippo pathway (like FAT1, LATS1/2, YAP fusions, or WWTR1-CAMTA1).
- You need to have a stored tumor sample from a previous biopsy or be willing to have a new biopsy taken for this study.
- Your cancer must be measurable on scans (like CT or MRI).
- You must be in fairly good health overall (able to do daily activities without help).
- You cannot have active cancer spread to the brain causing symptoms, serious heart problems, or be taking medicines that interfere with the study drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests SGN1 in people with advanced solid tumors whose cancer has grown despite standard treatments, or who could not tolerate them. The study aims to find a safe dose and see whether the drug can work in certain cancer types.
This trial tests a new drug called SYS6023 for people with advanced solid tumors that have not responded to standard treatments. It may be an option if your tumor has a specific protein called HER3 or certain genetic changes.
This study tests a combination of two investigational drugs (Simmitinib and SG001) in people with advanced solid tumors that have not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth, and to find the best dose for further studies.
This trial tests a new drug called ISM6331 for people with advanced mesothelioma or other solid tumors that have not responded to standard treatments. The drug targets a specific pathway that may help stop tumor growth.
This early study tests a new medicine (BPI-460372) in adults with advanced solid cancers that have come back or can’t be treated with standard options. It may help by targeting specific cancer changes in certain tumors, and doctors will also learn the safest dose.
This early-phase trial studies OMTX705, given by itself or with an anti–PD-1 immune therapy, in people with advanced solid cancers that can’t be cured or that stopped responding to standard treatments. It aims to check safety and see whether the treatment can shrink tumors or control disease.
Hear when a new Advanced Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.